Abstract
In parallel with the evolution of the dual antiplatelet therapy (DAPT) regimen, stent technology has matured from bare metal stents (BMS) over first generation to now second generation drug-eluting stents (DES) and improvements in stent technology have direct implications for the clinical strategy of DAPT. The use of newer generation DES has rapidly increased and is currently implanted in approximately 85% of patients undergoing percutaneous coronary intervention (PCI). In patients with acute coronary syndrome (ACS) undergoing PCI, the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines recommend that a P2Y12 inhibitor is maintained over 12 months in addition to aspirin, unless there are contraindications such as excessive risk of bleeding. Seminal trials have delineated the current recommendations on DAPT in patients with and without ACS. Randomized controlled trials (RCT) suggest that shorter durations of DAPT are safe with newer stent platforms.
| Original language | English |
|---|---|
| Title of host publication | Interventional Cardiology |
| Subtitle of host publication | Principles and Practice |
| Publisher | wiley |
| Pages | 436-442 |
| Number of pages | 7 |
| ISBN (Electronic) | 9781118983652 |
| ISBN (Print) | 9781118976036 |
| DOIs | |
| State | Published - 21 Nov 2016 |
Keywords
- Acute coronary syndrome
- Atrial fibrillation
- Bare metal stents
- Drug-eluting stents
- Dual antiplatelet therapy
- Percutaneous coronary intervention
- Randomized controlled trials
- Stent technology evolution